Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma × Docetaxel × Clear all

Phase

Phase 3 6 Phase 2 5 Phase 1 3 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 44 Prostatic Neoplasms 27 Breast Neoplasms 20 Lung Neoplasms 14 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Esophageal Neoplasms 11 Neoplasm Metastasis 9 Neoplasms 8 Sarcoma 7 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 5 Colorectal Neoplasms 5 Carcinoma, Transitional Cell 5 Carcinoma, Renal Cell 5 Triple Negative Breast Neoplasms 4 Melanoma 4 Carcinoma, Ovarian Epithelial 4 Breast Neoplasms, Male 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms, Castration-Resistant 3 Non-Muscle Invasive Bladder Neoplasms 3 Leiomyosarcoma 3 Inflammatory Breast Neoplasms 3 Head and Neck Neoplasms 3 Advanced Solid Tumors 3 Solid Tumors 2 Liposarcoma 2 HER2-positive Breast Cancer 2

Interventions

pembrolizumab 9 Cetuximab 5 durvalumab 3 Paclitaxel 3 Nivolumab 3 Gemcitabine 3 Cyclophosphamide 3 poly ICLC 2 avelumab 2 Irinotecan 2 Ipilimumab 2 Cisplatin 2 Carboplatin 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 vistusertib 1 tislelizumab 1 tirbanibulin 1 spartalizumab 1 sonidegib 1 sitravatinib 1 repotrectinib 1 pralsetinib 1 pertuzumab 1 pepinemab 1 obinutuzumab 1 mogamulizumab 1 lutetium Lu 177 dotatate 1 lenvatinib 1 gedatolisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡